The M&A question is never far away for medtech companies that successfully restructure, set ambitious but achievable goals and whose portfolios and markets are relatively easily defined. Thus, device industry commentators have recently been prone to couple upper/lower extremities and biologics manufacturer Wright Medical Group NV, newly augmented by its 2015 Tornier NVacquisition, with suitors as the combined group continues to show robust financial performances.
Wright Place, Wright Time? Ortho Specialist's Focus Is Paying Off
In reinventing itself as a niche specialist in the orthopedic market, Wright Medical is putting efforts into maintaining leadership in the upper and lower extremities and building on its biologics strengths – a sales platform that was reinforced highly synergistically on the acquisition of Tornier. But for however long Wright Medical can remain independent, how does it balance value-based health care with strategic development plans?
More from Innovation
More from In Vivo
• By
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
• By
Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.
• By
During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.